Okogen, Inc., a developer of ophthalmic anti-infectives, received a notice of allowance from the United States Patent and Trademark Office for the use of ranpirnase for the treatment of viral conjunctivitis. “The claims granted under 3IPOK1.0002US, in combination with the our existing in-licensed portfolio, further reinforce our strong intellectual property position,” said Brian M. Strem, Ph.D., Chief Executive Officer of Okogen.